| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11304951 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11324751 | JANSSEN PHARMS | Dosing regimens associated with extended release paliperidone injectable formulations |
May, 2041
(17 years from now) | |
| US11666697 | JANSSEN PHARMS | Methods for ensuring resuspension of paliperidone palmitate formulations |
Nov, 2041
(17 years from now) | |
Invega Hafyera is owned by Janssen Pharms.
Invega Hafyera contains Paliperidone Palmitate.
Invega Hafyera has a total of 3 drug patents out of which 0 drug patents have expired.
Invega Hafyera was authorised for market use on 30 August, 2021.
Invega Hafyera is available in suspension, extended release;intramuscular dosage forms.
Invega Hafyera can be used as treatment of schizophrenia by administration of a six-month paliperidone palmitate injectable suspension filled syringe that has been shipped and stored in a horizonal position, reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose, treatment of schizophrenia by administering a dose up to two weeks before or three weeks after the scheduled six-month dose.
The generics of Invega Hafyera are possible to be released after 24 November, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 30 August, 2021
Treatment: Reinitiation of schizophrenia treatment wherein more than 6 months 3 weeks but less than 8 months have elapsed since the last dose; Treatment of schizophrenia by administering a dose up to two weeks b...
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA HAFYERA family patents
